Navigation Links
Keryx Biopharmaceuticals Announces Poster Presentations Highlighting Clinical Activity of KRX-0401 (Perifosine) at the Upcoming Annual Meeting of the American Society of Clinical Oncology
Date:5/18/2009

Results Will be Reported from Phase 2 Studies Evaluating KRX-0401 in Advanced Renal Cell Carcinoma, Colorectal Cancer and Gastrointestinal Stromal Tumors (GIST)

NEW YORK, May 18 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that four abstracts on KRX-0401 (Perifosine), the Company's Akt-inhibitor for cancer, were accepted for presentation during poster sessions taking place at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO), to be held in Orlando, Florida from May 29 to June 2.

All of the clinical data to be presented demonstrates the potential clinical efficacy of KRX-0401, both as a single agent and in combination with other approved agents, in the treatment of patients with advanced renal cell carcinoma, colorectal cancer and GIST.

Abstracts selected for presentation are as follows:

Renal Cell Carcinoma (RCC)

Friday, May 29th, 2009:

#5034: Phase II study of perifosine in metastatic renal cell carcinoma (RCC) progressing after prior therapy (Rx) with a VEGF receptor inhibitor.

Lead Author: Nicholas Vogelzang, MD

Poster Discussion: 5:00pm-6:00pm (Level 2, West Hall F5)

Sunday, May 31st, 2009:

#5101: A phase II trial of perifosine in patients with advanced renal cell carcinoma (RCC) who have failed tyrosine kinase inhibitors (TKI).

Lead Author: Daniel Cho, MD

Poster Session: 2:00pm - 6:00pm (Level 2, West Hall C)

Colorectal Cancer

Sunday, May 31st, 2009:

#4081: Randomized phase II study of perifosine in combination with capecitabine versus capecitabine alone in patients with second- or third-line metastatic colon cancer.

Lead Author: Sasha Vukelja, MD

Poster Session: 8:00am - 12:00pm (Level 2, West Hall C)

Gastrointestinal Stromal Tumor (GIST)

Sunday, May 31st, 2009:

#10563: A randomized phase II study of perifosine (P) plus imatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST).

Lead Author: Anthony Conley, MD

Poster Session: 2:00pm - 6:00pm (Level 2, West Hall C)

Copies of these abstracts are currently available and can be viewed on-line through the ASCO website: http://www.asco.org/.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM)(ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. The Company also actively engages in business development activities that include seeking strategic relationships for its product candidates and for the Company, as well as evaluating compounds and companies for in-licensing or acquisition. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future clinical and business prospects for KRX-0401, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully complete clinical trials for KRX-0401; our ability to meet anticipated development timelines for KRX-0401 due to recruitment, clinical trial results, manufacturing capabilities or other factors; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information in our website and in the American Society of Clinical Oncology's website is not incorporated by reference into this press release and is included as an inactive textual reference only.

    KERYX CONTACT: Lauren Fischer Director
                       Investor Relations
                       Keryx Biopharmaceuticals, Inc.
                       Tel: 212.531.5965
                       E-mail: lfischer@keryx.com


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2009 Financial Results on Thursday, May 14, 2009 at 8:30am EDT
2. Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer
3. Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research
4. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
6. Keryx Biopharmaceuticals Inc. Announces Receipt of Nasdaq Delisting Notification
7. Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
8. Keryx Biopharmaceuticals Notified that Nasdaq Has Extended Minimum Bid Price Rule Compliance Period
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
10. Keryx Biopharmaceuticals to Present at the Jefferies & Co. Healthcare Conference
11. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... 23, 2017  GlobeImmune, Inc. today announced it has ... of 12,835,490 shares of its common stock to NantCell, ... connection with the sale of its common stock, NantCell ... issue to GlobeImmune 200,000 shares, an estimated $2.0 million ... "We are pleased to enter into this strategic agreement ...
(Date:3/23/2017)... ... March 23, 2017 , ... Ellen Matloff, ... Connecticut Technology Council (CTC) as a 2017 Women of Innovation® finalist. Matloff will ... Innovation Awards Dinner. , The dinner recognizes women accomplished in science, technology, engineering ...
(Date:3/23/2017)... NetworkNewsWire Editorial Coverage  ... Cancer remains one of ... health care systems, in terms of costs and resources. However, ... the development of innovative and efficient therapies that demonstrate higher ... types of cancer treatments, a growing number of patients receiving ...
(Date:3/23/2017)... Colo. , March 23, 2017  Agriculture technology ... Series A financing and note conversion to commercialize its ... Planet is focused on developing products that are simultaneously ... $30 million in the last 18 months. This latest ... North Bridge Venture Partners. The company,s ...
Breaking Biology Technology:
(Date:3/1/2017)... , March 1, 2017  Aware, Inc. (NASDAQ: ... announced that Richard P. Moberg has resigned, ... co-President and Chief Financial Officer and Treasurer of Aware ... to serve as a member of the Board of ... , Aware,s co-Chief Executive Officer and co-President, General Counsel ...
(Date:2/26/2017)... , Feb. 25, 2017  Securus Technologies, ... technology solutions for public safety, investigation, corrections and ... Recidivism and Reentry. "Too often, too ... prisons and county jails are trying to tackle ... inmates and friends and family members. While significant steps ...
(Date:2/16/2017)...  Genos, a community for personal genetic discovery ... Laboratory Accreditation from the College of American Pathologists ... that meet stringent requirements around quality, accuracy and ... "Genos is committed to maintaining the highest ... to be receiving CAP accreditation," said Jill ...
Breaking Biology News(10 mins):